engleski

The changes in cellular immune response during prostate cancer and benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases in the urological practice. Significant advances have occurred in medical and surgical therapy, but immunological understanding of the biology of this disease is still less known. Prostate cancer is the most commonm malignant neoplasm in men, recording to the western literature sources. The ethiology of this malignancy is still unclear, but it is well known that includes risk factors such as age, ethnicity and family anamnesis. Naive and effector T cells are susceptible to tolerization, suggesting that tolerance can modify both the priming and effector phases of anti-tumor T cell responses. Peripheral blood lymphocytes (PBL) were isolated and their phenotypic profiles were analyzed together with expression of intracellular, cytolitic molecule perforin, using flow cytometric analysis (FACSCalibur). None of these patients had received anti-tumor or anti-inflammatory therapy. Statistical analysis was performed in computer program Statistica 7.1 (StatSoft, Inc., Tulsa, OK, USA). Our preliminary data indicate the statistical significant disproportion in all examine groups (the percentage of total perforin and the percentage of double positive cells: CD3+ P+, CD4+P+, CD8+P+, CD16+P+ and CD56+P+ cells), compared to healthy volunteers. According to our results, we can speculate that the role of perforin positive cells in innate immunity in patients with benign prostatic hyperplasia and prostate cancer is indicative, as well as, the cytotoxic activity of peripheral blood lymphocytes.

prostatic cancer; benign prostatic hyperplasia; perforin; cellular immunity

nije evidentirano